Citadel Advisors’s Tectonic Therapeutic TECX Stock Holding History

Citadel Advisors’s Portfolio TECX Stock Details TECX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,900	Closed	-$478K	–	14505
2025 Q4	$478K	Buy	+22,900	New	+$426K	﹤0.01%	9136
2024 Q2	–	Sell	-8	Closed	-$128	–	15620
2024 Q1	$128	Sell	8 -50	-86%	-$792	﹤0.01%	14415
2023 Q4	$952	Hold	58	–	–	﹤0.01%	13912
2023 Q3	$1.08K	Buy	+58	New	+$1.02K	﹤0.01%	13922
2023 Q2	–	Sell	-83	Closed	-$1K	–	15376
2023 Q1	$1K	Buy	83 +66	+388%	+$919	﹤0.01%	14382
2022 Q4	$143	Buy	+17	New	+$150	﹤0.01%	14751
2021 Q4	–	Sell	-883	Closed	-$59K	–	14932
2021 Q3	$59K	Buy	+883	New	+$72.5K	﹤0.01%	13278
2021 Q2	–	Sell	-1,742	Closed	-$265K	–	14572
2021 Q1	$265K	Buy	+1,742	New	+$283K	﹤0.01%	11130

Other funds holding TECX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors's TECX Position: Q1 2026 in Review

Citadel Advisors sold out of Tectonic Therapeutic (TECX) in Q1 2026, closing a stake of 317,617 shares — an estimated $7.82M sold.

Citadel Advisors first reported a position in TECX in Q2 2018 and held it in 28 quarters. The position peaked at $77.4M in Q3 2018. 111 funds tracked by Wall St. Rank hold TECX as of Q1 2026.

Citadel Advisors reported no remaining Tectonic Therapeutic position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 317,617 Tectonic Therapeutic shares in Q1 2026, an estimated $7.82M.
Citadel Advisors first reported a position in Tectonic Therapeutic in Q2 2018 and held it in 28 quarters.
Citadel Advisors's Tectonic Therapeutic position peaked at $77.4M in Q3 2018.
111 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.